MedicalResearch.com Interview with:
Dr. Mauricio F. Farez
Center for Research on Neuroimmunological Diseases (CIEN)
Raúl Carrea Institute for Neurological Research (FLENI)
Buenos Aires, Argentina
Medical Research: What is the background for this study? What are the main findings?
Dr. Farez: We were intrigued by our initial observation that Multiple Sclerosis (MS) relapses have a clear seasonal occurrence with less relapses during fall and winter. We found that melatonin levels (a hormone secreted by the pineal gland in the absence of light) have an inverse correlation with Multiple Sclerosis relapses. Moreover, melatonin controls the generation of pathogenic Th17 cells, while it boosts the generation of regulatory Tr1 cells. By affecting the immune balance of those cells it may prevents the occurrence of relapse.
Medical Research: What should clinicians and patients take away from your report?
Dr. Farez: Melatonin and drugs alike targeting its pathways may be a future alternative in Multiple Sclerosis treatment. Until a proper clinical trial is conducted, melatonin SHOULD NOT be used as Multiple Sclerosis therapy. I would like to emphasize this, because melatonin is a complex hormone with receptors present basically in every cell. We do not know yet the dosage and administration form needed to obtain similar effects as the one observed in our in vitro and animal studies.